Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-01

Study Completion Date

2024-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.

NCT01426243

HIV Infection Yellow Fever

COMPLETED PHASE3

Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals

NCT03132311

HIV Infections

RECRUITING PHASE4

"Persistence of Neutralizing Antibodies Against Yellow Fever (YF) in HIV-infected Patients"

NCT03591003

HIV Infections Yellow Fever Vaccine

COMPLETED

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected

NCT05075044

HIV Infections COVID-19

UNKNOWN PHASE4

An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

NCT00027365

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The vaccine responses will be determined with the measurement of the neutralizing antibody titers using the neutralization tests PRNT and Pseudo type ACN 400 to M120 (ten years) in the participants of the ANRS EP 46 NOVAA trial, VIH+ and controls naïve to previous vaccination ten years after a primary anti-yellow fever vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Yellow Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Category 2, multi-centric intervention research comparing 2 parallel groups of 40 HIV + subjects and 20 HIV- subjects included in the ANRS EP46 NOVAA trial.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV+ GROUP

Subjects included in the ANRS EP 46 NOVAA trial:

• 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \> 350/mm3 and a viral load \<50 copies / mL for at least 6 months).

Group Type ACTIVE_COMPARATOR

Yellow fever vaccination (STAMARIL)

Intervention Type BIOLOGICAL

Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects

HIV- GROUP

Subjects included in the ANRS EP 46 NOVAA trial:

• 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.

Group Type OTHER

Yellow fever vaccination (STAMARIL)

Intervention Type BIOLOGICAL

Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Yellow fever vaccination (STAMARIL)

Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects included in the ANRS EP 46 NOVAA trial:

* 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \> 350/mm3 and a viral load \<50 copies / mL for at least 6 months).
* 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.
* Subjects agreeing to be monitored according to the terms of the protocol.
* Subjects affiliated to a Social Security scheme or beneficiaries of such a scheme.
* Signature of informed consent.